This inventor holds 11 USPTO granted patents. Top assignees: Chembiomed, Ltd., Polysar Limited, Atomic Energy of Canada Limited. Active years: 1977-1989.
Company Filing History:
8 out of 17 
2 out of 139 
1 out of 182 
Years Active: 1977-1989
Title: The Innovative Contributions of Raymond U. Lemieux
Introduction
Raymond U. Lemieux is a prominent inventor based in Edmonton, Canada. He has made significant contributions to the field of biochemistry, particularly in the synthesis of tumor antigenic determinants. With a total of 11 patents to his name, Lemieux's work has had a profound impact on cancer diagnostics.
Latest Patents
One of Lemieux's latest patents involves the synthesis of the human T-antigenic determinant 2-acetamido-2-deoxy-3-O-(β-D-galactopyranosyl)-α-D-galactopyranoside. This compound contains an α-O-glycosidically linked bridging arm O--(CH₂)n COR. The determinant is coupled to carrier molecules to form artificial T-antigens and to insoluble supports to create T-immunoadsorbents. Notably, the artificial T-antigen has been shown to elicit a delayed-type hypersensitivity reaction, serving as a diagnostic tool for the presence of cancer in humans.
Career Highlights
Throughout his career, Lemieux has worked with notable companies such as Chembiomed Ltd. and Polysar Limited. His innovative approaches and research have positioned him as a leader in his field, contributing to advancements in cancer research and diagnostics.
Collaborations
Lemieux has collaborated with esteemed colleagues, including Donald A. Baker and R. Murray Ratcliffe. These partnerships have further enhanced the scope and impact of his research.
Conclusion
Raymond U. Lemieux's contributions to the field of biochemistry and cancer diagnostics are noteworthy. His innovative patents and collaborations reflect his commitment to advancing medical science and improving diagnostic methods for cancer detection.